Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1244]

Zanubrutinib improves PFS compared to ibrutinib for R/R chronic lymphocytic...

Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA

Zanubrutinib improves PFS compared to ibrutinib for R/R chronic lymphocytic leukaemia and small lymphocytic lymphoma ( Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA )

Adjuvant endocrine therapy +/- 1 year of everolimus fails to improve iDFS and...

Dr Mariana Chavez Mac Gregor - MD Anderson Cancer Center, Houston, USA

Adjuvant endocrine therapy +/- 1 year of everolimus fails to improve iDFS and OS in patients with high-risk HR+, HER2-negative BC ( Dr Mariana Chavez Mac Gregor - MD Anderson Cancer Center, Houston, USA )

Camizestrant may be superior to fulvestrant in patients with hormone receptor...

Dr Mafalda Oliveira - Vall d’Hebron University Hospital, Barcelona, Spain

Camizestrant may be superior to fulvestrant in patients with hormone receptor-positive, HER2-negative breast cancer ( Dr Mafalda Oliveira - Vall d’Hebron University Hospital, Barcelona, Spain )

Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable...

Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA

Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable results against R/R diffuse large B-cell lymphoma ( Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA )

Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable...

Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA

Teclistamab in combination with subcutaneous daratumumab and lenalidomide shows...

Dr Emma Searle - University of Manchester, Manchester, UK

Teclistamab in combination with subcutaneous daratumumab and lenalidomide shows promising results in patients with multiple myeloma ( Dr Emma Searle - University of Manchester, Manchester, UK )

Access to Oncology Medicines Coalition - The Medicines Patent Pool

Charles Gore - Medicines Patent Pool, Geneva, Switzerland

Access to Oncology Medicines Coalition - The Medicines Patent Pool ( Charles Gore - Medicines Patent Pool, Geneva, Switzerland )

Final OS analysis of ICARIA-MM: Isatuximab triplet shows continued survival...

Dr Paul Richardson - Dana Farber Cancer Institue, Boston, USA

Final OS analysis of ICARIA-MM: Isatuximab triplet shows continued survival benefit in R/R multiple myeloma ( Dr Paul Richardson - Dana Farber Cancer Institue, Boston, USA )

ESMO 2022: Lung roundup

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

ESMO 2022: Lung roundup ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

Xevinapant plus standard of care chemoradiotherapy improved 5 year OS for...

Prof Jean Bourhis - University Hospital of Lausanne, Lausanne, Switzerland

Xevinapant plus standard of care chemoradiotherapy improved 5 year OS for unresected LA SCCHN ( Prof Jean Bourhis - University Hospital of Lausanne, Lausanne, Switzerland )

Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced...

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA

Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )

ESMO 2022: Breast and ovarian trial analysis

Dr Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2022: Breast and ovarian trial analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

More from ecancer